Navigation Links
Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
Date:7/16/2009

PORTON DOWN, England, July 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS).

The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. The two licenses with RMS complement Enigma's existing patent portfolio as well as intellectual property licensed by Celera Diagnostics for real-time PCR thermal cyclers.

Enigma is currently developing a series of highly multiplexed, HybProbe assays for its infectious disease programs including pandemic and seasonal influenza, chlamydia and MRSA. These tests will be combined with Enigma's revolutionary fully automated real-time PCR system, the Enigma ML (mini-laboratory), enabling fast and accurate 'test and treat' molecular diagnostics at point-of-care.

Financial terms were not disclosed.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licenses from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc
    212-827-0020
    Andrew Mielach - Media
    amielach@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
2. New light shed on the enigma of salt intake and hypertension
3. The Marketing Enigma
4. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
5. Ridge Diagnostics Wins Growth-Promoting Loan From Biotech Center
6. Quest Diagnostics To Release Second Quarter Financial Results
7. Quest Diagnostics Earns Platinum Honor As Best Employer For Healthy Lifestyles
8. Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market
9. Quest Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
10. Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference
11. Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 2017 , ... Hospital M&A activity slowed in the second quarter of 2017, ... rose to 23 in the second quarter, up 15% from the 20 publicly announced ... deals in the year-ago second quarter. Only four of the transactions disclosed a purchase ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched a ... acceptance to a residency in a United States hospital. Being accepted into a ... , According to data released by the ECFMG®, every year, 50 percent of ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... (PRWEB) , ... July 20, ... ... provider of enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, ... world’s largest healthcare services providers. , According to Peter Ohrenberger, sales director ...
(Date:7/20/2017)... ... ... Doctors on Liens, the leading network of medical providers working on a ... Russell Horine, DC to their exclusive list of medical professionals. Horine Chiropractic is a ... the clinic director and his son Dr. Lee Horine and daughter-in-law Dr. Natalie Horine ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Zymo Research Corp., also known as ,The Epigenetics Company, announced today ... a precise manner using the myDNAge ™ test. Based on Horvath,s ... human genetics and biostatistics at the David Geffen School of Medicine ... Research,s proprietary DNAge ™ technology is used to analyze DNA methylation ... ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
Breaking Medicine Technology: